Diabetes mellitus and heart disease

References

[1] Low Wang CC,Hiatt WR.Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations.Circulation2016;133:2459-502 PMCID:PMC4910510

[2] Einarson TR,Ludwig C.Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.Cardiovasc Diabetol2018;17:83 PMCID:PMC5994068

[3] Paulus WJ.Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction.JACC Heart Fail2018;6:1-7

[4] Af Geijerstam P,Nyström FH.Smoking and cardiovascular disease in patients with type 2 diabetes: a prospective observational study.J Cardiovasc Med2023;24:802-7 PMCID:PMC10552835

[5] Petrie JR,Touyz RM.Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms.Can J Cardiol2018;34:575-84 PMCID:PMC5953551

[6] Myers MG Jr,Seeley RJ.Obesity and leptin resistance: distinguishing cause from effect.Trends Endocrinol Metab2010;21:643-51 PMCID:PMC2967652

[7] Keating ST,El-Osta A.Epigenetic changes in diabetes and cardiovascular risk.Circ Res2016;118:1706-22 PMCID:PMC5593074

[8] Reichert S,Santos AN.Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease.Atherosclerosis2017;266:234-9

[9] Chandrasekaran P.Cellular and molecular mechanisms of insulin resistance.Curr Tissue Microenviron Rep2024;Online ahead of print:

[10] Li Y,Liu S.Diabetic vascular diseases: molecular mechanisms and therapeutic strategies.Signal Transduct Target Ther2023;8:152 PMCID:PMC10086073

[11] Falck-Hansen M,Monaco C.Toll-like receptors in atherosclerosis.Int J Mol Sci2013;14:14008-23 PMCID:PMC3742229

[12] Peerschke EI,Ghebrehiwet B.Complement activation on platelets: implications for vascular inflammation and thrombosis.Mol Immunol2010;47:2170-5 PMCID:PMC2904326

[13] Seneviratne A,Holvoet P.Biomechanical factors and macrophages in plaque stability.Cardiovasc Res2013;99:284-93

[14] Bugger H.Molecular mechanisms of diabetic cardiomyopathy.Diabetologia2014;57:660-71 PMCID:PMC3969857

[15] Hansen SS,Hafstad AD.The role of NADPH oxidases in diabetic cardiomyopathy.Biochim Biophys Acta Mol Basis Dis2018;1864:1908-13

[16] Chandrasekaran P.The role of obesity in type 2 diabetes mellitus-an overview.Int J Mol Sci2024;25:1882 PMCID:PMC10855901

[17] Verma SK,Kishore R.Mitochondrial dysfunction and its impact on diabetic heart.Biochim Biophys Acta Mol Basis Dis2017;1863:1098-105 PMCID:PMC5332436

[18] Jubaidi FF,Mariappan V.Mitochondrial dysfunction in diabetic cardiomyopathy: the possible therapeutic roles of phenolic acids.Int J Mol Sci2020;21:6043 PMCID:PMC7503847

[19] Hsueh WA.Renin-angiotensin-aldosterone system in diabetes and hypertension.J Clin Hypertens (Greenwich)2011;13:224-37 PMCID:PMC8673350

[20] Forbes JM.Mechanisms of diabetic complications.Physiol Rev2013;93:137-88

[21] Rubin J,Chambless LE.Hyperglycemia and arterial stiffness: the atherosclerosis risk in the communities study.Atherosclerosis2012;225:246-51 PMCID:PMC3936879

[22] Chandrasekaran P.The role of SCAP/SREBP as central regulators of lipid metabolism in hepatic steatosis.Int J Mol Sci2024;25:1109 PMCID:PMC10815951

[23] Walther TC.Lipid droplets and cellular lipid metabolism.Annu Rev Biochem2012;81:687-714 PMCID:PMC3767414

[24] Puri R,Shao M.Non-HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events.Arterioscler Thromb Vasc Biol2016;36:2220-8

[25] Trpkovic A,Stanimirovic J.Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases.Crit Rev Clin Lab Sci2015;52:70-85

[26] Azevedo A,Antonio RC,Gerlach RF.Matrix metalloproteinases are involved in cardiovascular diseases.Basic Clin Pharmacol Toxicol2014;115:301-14

[27] Wheeler S,Forsberg CW.Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.Diabetologia2013;56:1934-43

[28] Kernan WN,Furie KL.IRIS Trial InvestigatorsPioglitazone after ischemic stroke or transient ischemic attack.N Engl J Med2016;374:1321-31 PMCID:PMC4887756

[29] Viscoli CM,Carolei A.IRIS Trial investigatorsPioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the insulin resistance intervention after stroke trial.Am Heart J2014;168:823-9.e6 PMCID:PMC4254508

[30] Marso SP,Brown-Frandsen K.LEADER Steering CommitteeLEADER Trial InvestigatorsLiraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med2016;375:311-22 PMCID:PMC4985288

[31] Heller SR,Iqbal A,Wagner L.A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.Diabetologia2022;65:55-64 PMCID:PMC8660716

[32] Marso SP,Consoli A.SUSTAIN-6 InvestigatorsSemaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med2016;375:1834-44

[33] Berry S,Acs A.Calibration of the IQVIA core diabetes model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.J Med Econ2023;26:1019-31

[34] Mima A,Nakamoto T.Effects of oral semaglutide on renal function in diabetic kidney disease: a short-term clinical study.In Vivo2024;38:308-12 PMCID:PMC10756470

[35] Zinman B,Lachin JM.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med2015;373:2117-28

[36] Krämer BK,Chilton R.Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.J Diabetes Complications2023;37:108588

[37] Wanner C,Kraus BJ.How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.Nephrol Dial Transplant2024;Online ahead of print:gfae032

[38] Talha KM,Butler J.SGLT-2 inhibitors in heart failure: a review of current evidence.Int J Heart Fail2023;5:82-90 PMCID:PMC10172076

[39] Lopaschuk GD.Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review.JACC Basic Transl Sci2020;5:632-44 PMCID:PMC7315190

[40] Green JB,D'Agostino RB.Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.Am Heart J2018;203:30-8

[41] Holman RR,Mentz RJ.EXSCEL Study GroupEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.N Engl J Med2017;377:1228-39 PMCID:PMC9792409

[42] Husain M,Donsmark M.PIONEER 6 InvestigatorsOral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med2019;381:841-51

[43] Pfeffer MA,Diaz R.ELIXA InvestigatorsLixisenatide in patients with type 2 diabetes and acute coronary syndrome.N Engl J Med2015;373:2247-57

[44] Gerstein HC,Dagenais GR.REWIND InvestigatorsDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.Lancet2019;394:121-30

[45] Wiviott SD,Bonaca MP.DECLARE-TIMI 58 InvestigatorsDapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med2019;380:347-57

[46] Cannon CP,Dagogo-Jack S.VERTIS CV InvestigatorsCardiovascular outcomes with ertugliflozin in type 2 diabetes.N Engl J Med2020;383:1425-35

[47] Xie X,Hao Y.Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review.Front Endocrinol2023;14:1301093 PMCID:PMC10766371